Physician profile
Gerald Gibbons
NPI 1336147883
$1,811.89
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $844 · 2020: $230 · 2021: $157 · 2022: $309 · 2023: $248 · 2024: $24.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $273.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $272.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $381.13 | 2019-2023 | Repatha, Otezla |
| Lilly USA, LLC | $232.85 | 2019-2023 | Mounjaro |
| Novo Nordisk INC | $213.69 | 2019-2023 | Wegovy, Rybelsus, Ozempic |
| Novartis Pharmaceuticals Corporation | $206.83 | 2019-2022 | |
| Pfizer INC. | $125.36 | 2019-2023 | |
| Amarin Pharma, INC. | $86.83 | 2019-2020 | |
| Glaxosmithkline, LLC. | $84.39 | 2019-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $54.26 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $51.16 | 2019-2023 | Spravato |
| Abbvie INC. | $49.21 | 2021 | |
| Sanofi-Aventis U.S. LLC | $48.49 | 2019 | |
| Sanofi Pasteur INC. | $46.65 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $39.71 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.49 | 2022-2023 | |
| Genentech USA, INC. | $24.57 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $24.32 | 2024 | Freestyle Libre 3 |
| Boston Scientific Corporation | $24.26 | 2019-2020 | |
| Daiichi Sankyo INC. | $19.96 | 2022 | |
| Mylan Specialty L.P. | $16.66 | 2019 | |
| Radius Health, INC. | $14.61 | 2022 | |
| Mannkind Corporation | $14.42 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Gibbons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.